
    
      This is a Phase 2 open label, two treatment cohort trial evaluating the addition of
      ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in
      subjects with CLL, who fail to achieve MRD negativity, after a minimum 6-month treatment with
      ibrutinib, alacabrutinib or venetoclax.
    
  